Catanzaro, Italy: The availability of low-THC, high-CBD cannabis products in Italy is associated with a reduction in the use of prescription drugs, according to data published in the Journal of Health Economics.
A team of international investigators from France, Germany, Italy, and the Netherlands assessed the relationship between adults’ access to low-THC (below 0.6 percent THC) cannabis and prescription drug sales in 106 Italian provinces over a two-year period.
They reported, “[L]ocal availability of light cannabis [low-THC, CBD-based products] led to a significant decrease in the number of dispensed boxes of anxiolytics by approximately 11.5 percent, a reduction of dispensed sedatives by 10 percent and a reduction of dispensed anti-psychotics by 4.8 percent.”
Researchers also identified less significant reductions in the use of anti-epileptic medications, anti-depressants, opioids, and migraine drugs.
They concluded: “[T]his [data] represents the first-ever evidence from Europe on the substitution effects induced by a compound of cannabis, CBD. As the product is increasingly available in other …. Countries, our results provide relevant implications for policymakers.”
Full text of the study, “Do-It-Yourself medicine? The impact of light cannabis liberalization on prescription drugs,” appears in the Journal of Health Economics. Additional information on CBD is available from the NORML fact sheet.
The post Availability of Low-THC Cannabis Products Associated with Reduced Use of Prescription Anxiolytics, Sedatives appeared first on NORML.Read MoreNews Releases – NORML